Related Experiment Videos
Allergen immunotherapy: exploring areas for further inquiry.
Tam Ramsey1, Wanda Lai1, Peter F Svider1
1Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI.
International Forum of Allergy & Rhinology
|October 13, 2017
Summary
Allergen immunotherapy research shows declining industry funding and fewer pollen allergy trials. Food and animal allergy research is increasing, but otolaryngologists lead few clinical trials.
Area of Science:
- Immunology
- Clinical Research
- Public Health
Background:
- Allergy-related illnesses affect millions globally.
- Understanding current research trends in allergen immunotherapy is crucial.
- National Institutes of Health (NIH)-supported research provides valuable insights.
Purpose of the Study:
- To characterize trends in clinical trials for allergen immunotherapy.
- To describe the landscape of allergen immunotherapy research funded by the NIH.
- To identify shifts in research focus and principal investigator demographics.
Main Methods:
- Searched ClinicalTrials.gov for "allergen immunotherapy" and "allergy immunotherapy."
- Collected data on trial completion, dates, design, population, funder, location, and allergen.
- Utilized NIH Research Portfolio Online Reporting Tools (RePORTER) for funding data.
Main Results:
- 372 clinical trials met inclusion criteria.
- Industry-funded trials decreased over 15 years; pollen allergy research declined, while food and animal allergy research increased.
- Otolaryngologists constituted only 6.4% of principal investigators; NIH funding totaled $74,986,125 over 118 years.
Conclusions:
- Otolaryngologists are underrepresented as principal investigators in allergen immunotherapy research.
- A significant decline in industry sponsorship for allergen immunotherapy trials is evident.
- These trends may inform future resource allocation and research priorities in allergen immunotherapy.